Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

MedAlert Tag: Cancer

XELJANZ MAY INCREASE RISK OF HEART PROBLEMS AND CANCER

January 12, 2021

The FDA alerted the public that preliminary results from a safety clinical trial found an increased risk of serious heart related problems and cancer with Xeljanz (tofacitinib) and Xeljanz XR. These drugs are indicated for the treatment of rheumatoid arthritis, which may develop in workers’ comp populations due to cumulative or acute trauma, or when a pre-existing inflammatory joint disease is made worse by an occupational injury.